Epithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma

被引:3
|
作者
Font, Albert [1 ,2 ]
de Porras, Vicenc Ruiz [2 ,3 ]
Valderrama, Begona P. [4 ]
Ramirez, Jose Luis [5 ]
Nonell, Lara [6 ]
Virizuela, Jose Antonio [7 ]
Anido, Urbano [8 ]
Gonzalez-del-Alba, Aranzazu [9 ]
Lainez, Nuria [10 ]
Llorente, Maria del Mar [11 ]
Jimenez, Natalia [12 ]
Mellado, Begona [13 ]
Garcia-Donas, Jesus [14 ]
Bellmunt, Joaquim [15 ]
机构
[1] Univ Hosp Germans Trias & Pujol, Catalan Inst Oncol, Dept Med Oncol, Ctr Can Ruti Cami Ies Escoles S-N, Badalona 08916, Spain
[2] Badalona Appl Res Grp Oncol B ARGO, Catalan Inst Oncol, Ctra Can Ruti Cami Escoles S-N, Badalona 08916, Spain
[3] Germans Trias & Pujol Res Inst IGTP, Ctra Can Ruti Cami Escoles S-N, Badalona 08916, Spain
[4] Hosp Univ Virgen Rocio, Dept Med Oncol, Seville 41013, Spain
[5] Univ Hosp Germans Trias & Pujol, Catalan Inst Oncol, Dept Haematol, Ctr Can Ruti Cami Escoles S-N, Badalona 08916, Spain
[6] Hosp Mar Med Res Inst IMIM, MARGen, Barcelona 08003, Spain
[7] Hosp Univ Virgen Macarena, Dept Med Oncol, Seville 41009, Spain
[8] Complejo Hosp Univ Santiago, Dept Med Oncol, Santiago De Compostela 15706, Spain
[9] Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, Madrid 28222, Spain
[10] Complejo Hosp Navarra, Dept Med Oncol, Pamplona 31008, Spain
[11] Hosp Gen Univ Elda, Dept Med Oncol, Alicante 03600, Spain
[12] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Translat Genom & Targeted Therapeut Solid Tumors, Barcelona 08036, Spain
[13] Univ Barcelona, Hosp Clin Barcelona, Dept Med Oncol, IDIBAPS, Barcelona 08036, Spain
[14] HM Hosp Ctr Integral Oncol Hosp Madrid, Div Med Oncol, Madrid 28050, Spain
[15] Beth Israel Deaconess Med Ctr, Div Hematol & Oncol, Boston, MA 02215 USA
关键词
advanced urothelial cell carcinoma; vinflunine; chemotherapy resistance; epithelial-to-mesenchymal transition; maintenance therapy; SUPPORTIVE CARE; OPEN-LABEL; PHASE-III; LONG-TERM; CANCER; CHEMOTHERAPY; MULTICENTER; EXPRESSION; PLUS; ATEZOLIZUMAB;
D O I
10.3390/cancers13246235
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Platinum-based chemotherapy is the first-line treatment for advanced urothelial cell carcinoma (aUCC). After first-line treatment, we previously showed that maintenance therapy with vinflunine improves progression-free survival. However, some patients are resistant to vinflunine and the specific mechanisms of resistance in aUCC are unclear. We analyzed the genomic landscape and the biological processes potentially related to vinflunine activity and found that epithelial-to-mesenchymal transition (EMT) plays a pivotal role as a resistance mechanism. In experiments with cell lines, curcumin reversed EMT and sensitized cells to vinflunine. We suggest that EMT mediates resistance to vinflunine and that the reversion of this process could enhance the effect of vinflunine in aUCC patients. In the phase II MAJA trial, maintenance therapy with vinflunine resulted in longer progression-free survival compared to best supportive care in advanced urothelial cell carcinoma (aUCC) patients who did not progress after first-line platinum-based chemotherapy. However, despite an initial benefit observed in some patients, unequivocal resistance appears which underlying mechanisms are presently unknown. We have performed gene expression and functional enrichment analyses to shed light on the discovery of these underlying resistance mechanisms. Differential gene expression profile of eight patients with poor outcome and nine with good outcome to vinflunine administered in the MAJA trial were analyzed. RNA was isolated from tumor tissue and gene expression was assessed by microarray. Differential expression was determined with linear models for microarray data. Gene Set Enrichment Analysis (GSEA) was used for the functional classification of the genes. In vitro functional studies were performed using UCC cell lines. Hierarchical clustering showed a differential gene expression pattern between patients with good and poor outcome to vinflunine treatment. GSEA identified epithelial-to-mesenchymal transition (EMT) as the top negatively enriched hallmark in patients with good outcome. In vitro analyses showed that the polyphenol curcumin downregulated EMT markers and sensitized UCC cells to vinflunine. We conclude that EMT mediates resistance to vinflunine and suggest that the reversion of this process could enhance the effect of vinflunine in aUCC patients.
引用
收藏
页数:18
相关论文
共 50 条
  • [41] Arrestin 3 Mediates a Mesenchymal to Epithelial Transition in Renal Cell Carcinoma Cells
    Masannat, J.
    Russin, M.
    Daaka, Y.
    MOLECULAR BIOLOGY OF THE CELL, 2016, 27
  • [42] Vinflunine in routine practice for the treatment of advanced or metastatic urothelial cell carcinoma in Germany
    Hegele, A.
    De Geeter, P.
    Goebell, P.
    Matz, U.
    De Schultz, W.
    Retz, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S669 - S669
  • [43] The role of RhoC in epithelial-to-mesenchymal transition of ovarian carcinoma cells
    Wen-feng Gou
    Yang Zhao
    Hang Lu
    Xue-feng Yang
    Yin-ling Xiu
    Shuang Zhao
    Jian-min Liu
    Zhi-tu Zhu
    Hong-zhi Sun
    Yun-peng Liu
    Feng Xu
    Yasuo Takano
    Hua-chuan Zheng
    BMC Cancer, 14
  • [44] Mathematical Modeling of Epithelial-to-Mesenchymal Transition in Thyroid Carcinoma Progression
    Sundling, Kaitlin
    Buehler, Darya
    Guo, Zhenying
    Hardin, Heather A.
    Mandal, Rakesh
    Montemayor-Garcia, Celina
    Lloyd, Ricardo V.
    LABORATORY INVESTIGATION, 2016, 96 : 155A - 155A
  • [45] Epithelial-to-mesenchymal transition as the driver of changing carcinoma and glioblastoma microenvironment
    Majc, Bernarda
    Sever, Tilen
    Zaric, Miki
    Breznik, Barbara
    Turk, Boris
    Lah, Tamara T.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2020, 1867 (10):
  • [46] Revisiting Epithelial-to-mesenchymal Transition through Adenoid Cystic Carcinoma
    Siu, Amanda
    Lee, Casey
    Pham, Eric
    Ramos, Daniel M.
    ANTICANCER RESEARCH, 2012, 32 (09) : 3683 - 3688
  • [47] TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells
    Niwa, Naoya
    Tanaka, Nobuyuki
    Hongo, Hiroshi
    Miyazaki, Yasumasa
    Takamatsu, Kimiharu
    Mizuno, Ryuichi
    Kikuchi, Eiji
    Mikami, Shuji
    Kosaka, Takeo
    Oya, Mototsugu
    LABORATORY INVESTIGATION, 2019, 99 (11) : 1702 - 1713
  • [48] Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines
    Yang, Anthony D.
    Fan, Fan
    Camp, E. Ramsay
    van Buren, George
    Liu, Wenbiao
    Somcio, Ray
    Gray, Michael J.
    Cheng, Haiyun
    Hoff, Paulo M.
    Ellis, Lee M.
    CLINICAL CANCER RESEARCH, 2006, 12 (14) : 4147 - 4153
  • [49] The role of RhoC in epithelial-to-mesenchymal transition of ovarian carcinoma cells
    Gou, Wen-feng
    Zhao, Yang
    Lu, Hang
    Yang, Xue-feng
    Xiu, Yin-ling
    Zhao, Shuang
    Liu, Jian-min
    Zhu, Zhi-tu
    Sun, Hong-zhi
    Liu, Yun-peng
    Xu, Feng
    Takano, Yasuo
    Zheng, Hua-chuan
    BMC CANCER, 2014, 14
  • [50] Mathematical Modeling of Epithelial-to-Mesenchymal Transition in Thyroid Carcinoma Progression
    Sundling, Kaitlin
    Buehler, Darya
    Guo, Zhenying
    Hardin, Heather A.
    Mandal, Rakesh
    Montemayor-Garcia, Celina
    Lloyd, Ricardo V.
    MODERN PATHOLOGY, 2016, 29 : 155A - 155A